Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „dupilumab“
Suchtreffer
Begriffe & Kennungen
Dupixent · 4.5 · 71 Therefore, patients receiving dupilumab may receive concurrent inactivated or non-live vaccinations. For in
Eintrag öffnenDupixent · 4.5 · 9 dupilumab-treated and placebo-treated patients. No adverse interactions between either of the non-live vacci
Eintrag öffnenDupixent · 4.5 · An effect of dupilumab on the PK of co-administered medicinal products is not expected. Based on the populatio
Eintrag öffnenDupixent · 4.5 · An effect of dupilumab on the PK of co-administered medicinal products is not expected. Based on the populatio
Eintrag öffnenDupixent · 4.5 · In a clinical study of atopic dermatitis patients, the effects of dupilumab on the pharmacokinetics (PK) of CY
Eintrag öffnenDupixent · 4.5 · In a clinical study of atopic dermatitis patients, the effects of dupilumab on the pharmacokinetics (PK) of CY
Eintrag öffnenDupixent · 4.5 · Therefore, patients receiving dupilumab may receive concurrent inactivated or non-live vaccinations. For infor
Eintrag öffnenDupixent · 4.8 · 11 Eczema herpeticum Eczema herpeticum was reported in < 1% of the dupilumab groups and in < 1 % of the placeb
Eintrag öffnenDupixent · 4.8 · 12 respiratory tract infection was numerically higher with dupilumab (17.2%) compared to placebo (10.3%) in Eo
Eintrag öffnenDupixent · 4.8 · 13 Less than 1 % of patients who received dupilumab at approved dosing regimens exhibited high titer ADA respo
Eintrag öffnenDupixent · 4.8 · 14 The long-term safety of dupilumab was assessed in an open-label extension study (EXCURSION) in children 6 t
Eintrag öffnenDupixent · 4.8 · 15 Asthma The safety profile of dupilumab in the 96 weeks long term safety study (TRAVERSE) was consistent wit
Eintrag öffnenDupixent · 4.8 · 76 The long-term safety profile of dupilumab in EXCURSION was consistent with the safety profile observed in t
Eintrag öffnenDupixent · 4.8 · 77 The safety profile of dupilumab in the 96 weeks long term safety study (TRAVERSE) was consistent with the s
Eintrag öffnenDupixent · 4.8 · Adolescents (12 t o17 years of age) The safety of dupilumab was assessed in a study of 250 patients 12 to 17 y
Eintrag öffnenDupixent · 4.8 · Adolescents (12 to 17 years of age) The safety of dupilumab was assessed in a study of 250 patients 12 to 17 y
Eintrag öffnenDupixent · 4.8 · Antidrug Antibodies (ADA) responses were not generally associated with impact on dupilumab exposure, safety, o
Eintrag öffnenDupixent · 4.8 · Antidrug Antibodies (ADA) responses were not generally associated with impact on dupilumab exposure, safety, o
Eintrag öffnenDupixent · 4.8 · Approximately 1% of patients 1 year of age and older with EoE who received dupilumab 300 mg QW (≥40 kg), 300 m
Eintrag öffnenDupixent · 4.8 · Approximately 1% of patients 1 year of age and older with EoE who received dupilumab 300 mg QW (≥40 kg), 300 m
Eintrag öffnen